Search results for "MESH: Acute Disease"

showing 5 items of 5 documents

Bone marrow fat quantification of osteoporotic vertebral compression fractures: comparison of multi-voxel proton MR spectroscopy and chemical-shift g…

2011

Background Only a few studies have used in/opposed phase method for a quantitative evaluation of fat fraction in the spine. Purpose To compare multivoxel proton MR spectroscopy and chemical-shift gradient-echo MR imaging for bone marrow fat quantification in vertebral compression fractures (VCF). Material and Methods Vertebral marrow fat quantification in fifteen patients was measured at 3.0-T. Multi-voxel proton spectroscopy (MRS) and in/opposed-phase MR imaging using a fat map build with a triple-echo gradient-echo sequence was used. All the patients had benign vertebral collapse. Bone marrow fat content was evaluated by both techniques in compressed (acute or chronic) and in non-compress…

MaleIn vivo magnetic resonance spectroscopyMagnetic Resonance Spectroscopy[SDV]Life Sciences [q-bio]Fat quantificationcomputer.software_genreMESH: Magnetic Resonance Imaging030218 nuclear medicine & medical imagingMESH: Aged 80 and over0302 clinical medicineBone MarrowVoxelFractures CompressionMESH: Fractures CompressionAged 80 and overMESH: AgedMESH: Middle Aged[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingRadiological and Ultrasound TechnologyGeneral MedicineMiddle AgedCompression (physics)LipidsMagnetic Resonance Imagingmedicine.anatomical_structureAcute DiseaseSpinal FracturesMESH: Acute DiseaseFemaleMESH: Bone MarrowMESH: OsteoporosisAdultMESH: Spinal Fractures03 medical and health sciences[INFO.INFO-IM]Computer Science [cs]/Medical ImagingmedicineHumansRadiology Nuclear Medicine and imagingAgedMESH: HumansMESH: Magnetic Resonance Spectroscopybusiness.industryMESH: Chronic DiseaseVertebral compression fractureMESH: Adultmedicine.diseaseMESH: LipidsMr imagingMESH: MaleProton mr spectroscopyChronic DiseaseOsteoporosisBone marrowbusinessNuclear medicineMESH: Femalecomputer030217 neurology & neurosurgeryActa Radiologica
researchProduct

Emergence of Aspergillus fumigatus azole resistance in azole-naïve patients with chronic obstructive pulmonary disease and their homes.

2017

Azole-resistant Aspergillus fumigatus (ARAF) has been reported in patients with chronic obstructive pulmonary disease (COPD) but has not been specifically assessed so far. Here, we evaluated ARAF prevalence in azole-naïve COPD patients and their homes, and assessed whether CYP51A mutations were similar in clinical and environmental reservoirs. Sixty respiratory samples from 41 COPD patients with acute exacerbation and environmental samples from 36 of these patient's homes were prospectively collected. A. fumigatus was detected in respiratory samples from 11 of 41 patients (27%) and in 15 of 36 domiciles (42%). Cyp51A sequencing and selection on itraconazole medium of clinical (n = 68) and e…

Drug Resistance Fungal -- genetics0301 basic medicineAzolesMaleAntifungal AgentsExacerbationMESH: Fungal Proteins/isolation & purification[SDV]Life Sciences [q-bio]Colony Count MicrobialAspergillus fumigatusMESH: Aspergillus fumigatus/drug effectsMESH: Cytochrome P-450 Enzyme System/drug effectsMESH: GenotypePulmonary Disease Chronic ObstructivedwellingCytochrome P-450 Enzyme SystemGenotypePulmonary Disease Chronic Obstructive -- microbiologyPrevalenceProspective Studieschemistry.chemical_classificationMESH: AgedCOPDAzole-resistanceMESH: Middle AgedbiologyMESH: Drug Resistance Fungal/geneticsMold environmental exposureSciences bio-médicales et agricolesMiddle Aged3. Good healthMESH: Pulmonary Disease Chronic Obstructive/microbiology*MESH: Housing[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyAir Pollution IndoorAcute DiseaseDisease ProgressionMESH: Acute DiseaseMESH: Cytochrome P-450 Enzyme System/isolation & purificationMESH: Disease ProgressionFemalemedicine.drugmedicine.medical_specialtyEnvironmental EngineeringGenotypeItraconazoleMESH: Fungal Proteins/drug effects030106 microbiologyAspergillus fumigatus -- drug effects -- genetics -- isolation & purificationMESH: Azoles/pharmacology*Fungal Proteins -- drug effects -- isolation & purificationchronic obstructive pulmonary diseaseMicrobiologyFungal Proteins03 medical and health sciencesazole resistanceMESH: Air Pollution Indoor/analysis*Drug Resistance FungalInternal medicinemedicineCOPDHumansMESH: Aspergillus fumigatus/geneticsDwellingMESH: Colony Count MicrobialMESH: PrevalenceAgedAspergillusMESH: HumansAspergillus fumigatusAzoles -- pharmacologyelectrostatic dust collectorPublic Health Environmental and Occupational Healthmold environmental exposureElectrostatic dust collectorBuilding and Constructionmedicine.diseasebiology.organism_classificationMESH: MaleMESH: Prospective StudieschemistryCytochrome P-450 Enzyme System -- drug effects -- isolation & purificationHousingAzoleARAFMESH: Aspergillus fumigatus/isolation & purification*Antifungal Agents -- pharmacologyMESH: Antifungal Agents/pharmacology*MESH: FemaleAir Pollution Indoor -- analysisIndoor air
researchProduct

Eubacterial PCR for Bacterial Detection and Identification in 100 Acute Postcataract Surgery Endophthalmitis

2008

International audience; PURPOSE: To evaluate eubacterial PCR compared with conventional cultures for detection and identification of bacterial agents in ocular samples from patients with acute postcataract endophthalmitis. METHODS: Broad-range eubacterial PCR amplification was used, followed by direct DNA sequencing in ocular samples (aqueous humor, vitreous samples from tap or vitrectomy) from 100 consecutive patients presenting with acute postcataract endophthalmitis. Bacterial cultures were performed on the same ocular samples by using traditional methods (brain-heart infusion broth). RESULTS: At the time of admission, the detection rate was not significantly different between cultures a…

MaleMESH: Sequence Analysis DNAMicrobiological culturegenetic structuresmedicine.medical_treatmentAntibioticsVitrectomy[ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyMESH: Bacteriological TechniquesPolymerase Chain ReactionEye Infections Bacteriallaw.inventionPostoperative Complications0302 clinical medicineEndophthalmitislawRNA Ribosomal 16SMESH: Postoperative ComplicationsMedicineProspective StudiesComputingMilieux_MISCELLANEOUSPolymerase chain reactionMESH: AgedEndophthalmitis0303 health sciencesbiologyMESH: Eye Infections Bacterial3. Good healthMESH: RNA Ribosomal 16Smedicine.anatomical_structureAcute DiseaseMESH: Acute DiseaseFemaleDNA BacterialPars planamedicine.medical_specialtymedicine.drug_classMESH: Aqueous HumorAqueous Humor03 medical and health sciencesHumansMESH: Endophthalmitis[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyAgedBacteriological TechniquesPhacoemulsificationMESH: HumansBacteria030306 microbiologybusiness.industryMESH: Vitreous BodyMESH: Polymerase Chain ReactionSequence Analysis DNAEye infectionbiology.organism_classificationmedicine.diseaseMESH: DNA Bacterial[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyMESH: MaleMESH: Prospective Studieseye diseasesSurgeryVitreous BodyMESH: Bacteria030221 ophthalmology & optometrysense organs[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologybusinessMESH: FemaleBacteriaMESH: PhacoemulsificationInvestigative Opthalmology & Visual Science
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct

[Cost of hospital-based management of acute myeloid leukemia: from analytical to procedure-based tarification]

2006

International audience; The confrontation of the macro- and micro-economic approaches of hospital costs is a recurrent question, in particular for pathologies where length of stay is highly variable, like acute myeloid leukemias (AML). This monocentric and retrospective study compares direct hospital medical costs of induction and relapse treatment sequences for AML, valued according to four different approaches: the analytic accounting system of our hospital, the French Diagnosis Related Group (DRG) cost databases of hospital discharges (readjusted, or not, to actual hospital stay duration), and official tariffs from the new French DRG prospective payment system. The average cost of hospit…

MaleMESH: Remission InductionMESH : Retrospective StudiesMESH : RecurrenceMESH: Leukemia MyeloidMESH: Length of StayRecurrence[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyMESH : FemaleHospital Costshealth care economics and organizationsMESH: Diagnosis-Related GroupsMESH: Hospital CostsMESH: Middle AgedRemission InductionMESH : Acute DiseaseMiddle AgedMESH : AdultMESH : Diagnosis-Related GroupsMESH : Length of StayLeukemia MyeloidAcute DiseaseMESH : Leukemia MyeloidMESH: Acute Disease[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleMESH : Prospective Payment SystemFranceAdultAdolescent[SDV.IMM] Life Sciences [q-bio]/ImmunologyMESH : MaleMESH : Hospital CostsMESH: Prospective Payment SystemMESH : AdolescentHumansMESH : Middle AgedMESH : FranceDiagnosis-Related GroupsRetrospective StudiesMESH: AdolescentMESH : Remission InductionMESH: HumansProspective Payment SystemMESH : HumansMESH: Retrospective StudiesMESH: AdultLength of StayMESH: MaleMESH: RecurrenceMESH: FranceMESH: Female
researchProduct